DelveInsight’s “Prostate Cancer Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of all prostate cancer types , historical and forecasted epidemiology as well as the prostate cancer market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
Discover which therapies are expected to grab the Prostate Cancer Market Share @ Prostate Cancer Market Outlook
Key Takeaways from the Prostate Cancer Market Report
Stay ahead in the Prostate Cancer Therapeutics Market with DelveInsight’s Strategic Report @ Prostate Cancer Market Outlook
Prostate Cancer Epidemiology Segmentation in the 7MM
Download the report to understand which factors are driving Prostate Cancer Epidemiology trends @ Prostate Cancer Prevalence
Prostate Cancer Marketed Drugs
NUBEQA (darolutamide) is an oral androgen receptor inhibitor. It is indicated for the treatment of adult patients with nmCRPC and mCSPC/mHSPC in combination with docetaxel. NUBEQA is administered 600 mg, (two 300 mg tablets) orally twice daily. In 2023, Bayer reported that its global revenue from NUBEQA amounted to around USD 941 million.
ERLEADA is a next-generation oral androgen receptor inhibitor. It is indicated for the treatment of patients with mCSPC/mHSPC and nmCRPC. ERLEADA is administered 240 mg orally once daily. In 2023, Johnson & Johnson Innovative Medicine reported that its global revenue from ERLEADA amounted to USD 2,387 million.
XTANDI is an orally bioavailable, organic, non-steroidal small molecule targeting the AR with potential antineoplastic activity. It is indicated for the treatment of patients with CRPC, mCSPC/mHSPC, nmCRPC with biochemical recurrence at high risk for metastasis. XTANDI is administered 160 mg orally once daily. In 2023, Pfizer reported that its global revenue from XTANDI amounted to USD 1,191 million.
Prostate Cancer Emerging Drugs
Opevesostat is an oral, non-steroidal, and selective inhibitor of CYP11A1 discovered and developed by Orion and is being investigated for the treatment of hormone-dependent cancers, such as prostate cancer. In July 2024, Merck and Orion announced a mutual exercise of options providing Merck global exclusive rights to opevesostat for the treatment of mCRPC. Merck and Orion initiated OMAHA1 (NCT06136624) and OMAHA2a (NCT06136650), two pivotal Phase III clinical trials evaluating opevesostat in combination with hormone replacement therapy (HRT), for the treatment of certain patients with mCRPC. Final results from the OMAHA1 trial are expected in 2028 and OMAHA2a trial final results are anticipated in 2030. In addition to these, Merck has also presented updated CYPIDES Phase II results of opevesostat mCRPC at ESMO Congress 2024.
CAN-2409, Candel’s most advanced viral immunotherapy candidate, is a replication-defective adenovirus that delivers the herpes simplex virus thymidine kinase (HSV-tk) gene to cancer cells. Moreover, according to the company’s corporate presentation, the company expects to announce topline data from this clinical trial by Q4 2024 for its ongoing placebo-controlled, randomized pivotal Phase III clinical trial of CAN-2409 in patients with low-to-intermediate-risk, localized, non-metastatic-prostate-cancer-and-Phase-II-trial-for-patients-undergoing active surveillance for localized prostate cancer. The drug CAN-2409 is presently undergoing evaluation in a Phase I clinical trial to assess its safety and tolerability in patients.
KPG-121 is a modulator of the Cereblon (CRBN) E3 ubiquitin ligase complex CRL4-CRBN targeting rapid ubiquitination and degradation of casein kinase 1A1 (CK1a) and transcription factors Aiolos (IKZF3) and Ikaros (IKZF1). KPG-121 promotes anti-proliferation and anti-angiogenesis activities and enhances immunomodulatory properties. A Phase I study to evaluate the safety, pharmacokinetics, and efficacy of KPG-121 when combined with enzalutamide, abiraterone, or apalutamide for the treatment of patients with mCRPC or nmCRPC was completed in the US. KPG-121 was well tolerated and demonstrated a favorable pharmacokinetic profile as well as promising efficacy.
To learn more about Prostate Cancer treatment guidelines, visit @ Prostate Cancer Treatment Market Landscape
Prostate Cancer Drugs Market
Currently, the market holds a diverse range of therapeutic alternatives for treatment, including PARP inhibitors, androgen receptor inhibitors, CYP17 inhibitors, microtubule inhibitors, radioligand therapies, GnRH receptor antagonists, and others in different lines of treatment. Androgen receptor pathway inhibitors are a mainstay of treatment for patients with prostate cancer. There are currently four approved androgen receptor pathway inhibitors in the United States: three anti-androgens — apalutamide, enzalutamide, and darolutamide, as well as an androgen receptor pathway inhibitor, abiraterone acetate.
Prostate Cancer Market Outlook
Prostate cancer starts as localized prostate cancer when only found in the prostate and surgery or radiation can be used to treat it. Sometimes, hormone therapy might also be used. Increased sophistication of prostate imaging has allowed for the rapid emergence of focal therapies such as focal laser ablation, high-intensity focal ultrasound (HIFU), irreversible electroporation (IRE), photodynamic therapy (VTP), and focal cryotherapy. Radical prostatectomy can be open (ORP), laparoscopic (LRP), or robotic-assisted (RARP). ORP is the traditional method, whilst LRP and RARP are increasing in popularity.
Prostate Cancer Companies
Merck & Co, Pfizer, Orion, Zenith Epigenetics, ESSA Pharma, RhoVac, AstraZeneca, Advaxis, Inc., Tracon Pharmaceuticals Inc., Bristol-Myers Squibb, Laekna Limited, Bracco Diagnostics, Inc, Arvinas Inc, Epizyme, Regeneron Pharmaceuticals, Veru Inc., Eli Lilly and Company, Exelixis, Luye Pharma Group, Amgen, Innocrin Pharmaceutical, Bayer, Nymox Pharmaceutical, Matrix Biomed, Tavanta Therapeutics, Fortis Therapeutics, Inc., Janssen Research & Development, LLC, Clarity Pharmaceuticals, Leap Therapeutics, Hinova pharmaceuticals, Vaccitech, Cardiff Oncology, Suzhou Kintor Pharmaceuticals, Teneobio, Inc., Janux Therapeutics, Fusion Pharmaceuticals, Corbus Pharmaceuticals, BioXcel Therapeutics, Onxeo S.A, Ayala Pharmaceuticals, HOOKIPA Pharma, Nuvation Bio, Ambrx, enGene, Jemincare, CellVax Therapeutics, POINT Biopharma, Oncternal Therapeutics, Immunic AG, BioNTech SE, and others.
Learn more about the FDA-approved drugs for Prostate Cancer @ Drugs for Prostate Cancer Treatment
Scope of the Prostate Cancer Market Report
Table of Content
1. Key Insights
2. Report Introduction
3. Executive Summary of Prostate Cancer
4. Key Events
5. Epidemiology and Market Forecast Methodology
6. Prostate Cancer Market Overview at a Glance
7. Disease Background and Overview
8. Treatment and Management
9. Epidemiology and Patient Population
10. Patient Journey
11. Marketed drug
12. Emerging Drugs
13. Prostate Cancer: 7MM Analysis
14. Unmet Needs
15. SWOT Analysis
16. KOL Views
17. Market Access and Reimbursement
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 09650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
